Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Glioblastoma
- Focus Pharmacodynamics; Therapeutic Use
- 10 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 27 Apr 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 01 May 2015 Status changed from not yet recruiting to recruiting as per M.D. Anderson Cancer Center.